Pharming Group NV vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pharming Group NV (PHARM.AS)

Q3 202630 Jul – 29 Sep 2026

▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.
The guidance cut is the single biggest negative force behind the stock's move this period.
Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.
It is a new negative overhang that can affect the stock beyond the one-day drop.
Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.
These approvals are the main positive counterweight to the weak RUCONEST story.
CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.
An abrupt CEO departure is a fresh governance risk that can hold the stock back.

August 202630 Jul – 29 Sep 2026

▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.
The guidance cut is the single biggest negative force behind the stock's move this period.
Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.
It is a new negative overhang that can affect the stock beyond the one-day drop.
Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.
These approvals are the main positive counterweight to the weak RUCONEST story.
CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.
An abrupt CEO departure is a fresh governance risk that can hold the stock back.

Latest30 Jul – 29 Sep 2026

▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.
The guidance cut is the single biggest negative force behind the stock's move this period.
Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.
It is a new negative overhang that can affect the stock beyond the one-day drop.
Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.
These approvals are the main positive counterweight to the weak RUCONEST story.
CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.
An abrupt CEO departure is a fresh governance risk that can hold the stock back.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.